Head-to-head · Value Score
CoreAge Rx vs NewSelf
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, NewSelf a 87. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-nameNewSelf
#13 · Grade A- · Great Deal
Est. first month
$134.99/mo at every dose (as low as $99.97 on a longer plan)
Save ~90% vs brand-nameFDA warning letter. The FDA issued NewSelf Limited dba NewSelf a warning letter in February 2026. Check it on the FDA database.
Get this deal Full NewSelf review →The verdict
CoreAge Rx takes it on Value Score, 93 to 87 — an est. $99/mo first month, with no teaser step-up baked in. NewSelf isn't out of it: Someone who expects to titrate high and wants the price to stay where it started.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | NewSelf |
|---|---|---|
| Value Score | 93 (A+) | 87 (A-) |
| Est. first month | $99/mo | $134.99/mo at every dose (as low as $99.97 on a longer plan) |
| Save vs brand-name | ~89% | ~90% |
| Semaglutide | $99/mo | $134.99/mo at every dose (as low as $99.97 on a longer plan) |
| Tirzepatide | $149/mo | $224.99/mo at every dose (as low as $144.49 on a longer plan) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Flat — no step-up |
| Coverage | All 50 states | 49 states |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
NewSelf
NewSelf sells compounded semaglutide with B12 or glycine at $134.99 a month and compounded tirzepatide with B6 and glycine at $224.99, both held flat across every dose, in 49 states.
Why it's a deal
- The rate holds at every dose on both molecules — semaglutide across 0.25 mg to 2.5 mg, tirzepatide across 2.5 mg to 15 mg — so titrating up costs nothing extra
- Both products are compounded with B12, B6 or glycine rather than sold as bare molecules, and the formulation is stated on the product card
- HSA and FSA eligible, with the health screening, shipping and ongoing support inside the price
- Names the 49 states it covers rather than implying nationwide reach
The fine print
- The prominent $99.97 and $144.49 figures are plan floors, not the standing rates — those are $134.99 and $224.99
- Not available in Mississippi or Louisiana
- A "Tirzepatide Plus" tier at $399 a month sits above the standard product, so the flat-rate promise applies within a tier rather than across the range
- Compounded only — no FDA-approved brand-name route
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to NewSelf.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.